Darunavir Tablets
developed to target human immunodeficiency virus infection to support immune system health.
Strengths: 600 · 800mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Prezista
- Therapeutic class
HIV Protease Inhibitor
- Pharmacological class
Protease Inhibitor
- Contraindications
hypersensitivity to darunavir; severe hepatic impairment
- Precautions and warnings
monitor liver enzymes; risk of rash; follow the prescribed regimen
- Minor side effects
diarrhoea; nausea; headache
- Moderate side effects
rash; vomiting; abdominal pain
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Janssen
- Onset Time
varies per patient
- Duration
24 hours
- Storage instructions
Store below 30°C. Protect from moisture.
- Drug interactions
st. john's wort; atorvastatin; clopidogrel
Serious side effects
stevens-johnson syndrome — requires immediate medical attention; hepatotoxicity — requires immediate medical attention
Patient summary
developed to target human immunodeficiency virus infection to support immune system health.
Mechanism of action
Darunavir acts as an HIV protease inhibitor, preventing the virus from replicating by blocking the protease enzyme that breaks down precursor proteins in immature HIV cells.
Pregnancy and breastfeeding
Pregnancy: should be used during pregnancy only if the potential benefit justifies the potential risk. Breastfeeding: not recommended for HIV-positive mothers.
Darunavir Tablets
developed to target human immunodeficiency virus infection to support immune system health.
Editorial Notes
- Active ingredient(s): Darunavir
- Listed indication(s): HIV Infection
Usually available as
- 60 tablets - 600 mg1493-600-mg-17854
- 30 tablets - 800 mg1493-800-mg-17855